natgillin/translations-raw huggingface dataset:
Manic episodes in Bipolar I Disorder in children and adolescents Aripiprazole was studied in a 30-week placebo-controlled trial involving 296 children and adolescents (10 to 17 years), who met DSM-IV criteria (Diagnostic and Statistical Manual of Mental Disorders) for Bipolar I Disorder with manic or mixed episodes with or without psychotic features and had a YMRS score ≥ 20 at baseline.
Uporabo aripiprazola so raziskovali v 30-tedenskem s placebom nadzorovanem preskušanju, ki je vključevalo 296 otrok in mladostnikov (10 do 17 let), ki so ustrezali kriterijem DSM-IV (Diagnostic and Statistical Manual of Mental Disorders) za bipolarno motnjo I z maničnimi ali mešanimi epizodami s psihotičnimi lastnostmi ali brez njih, in so imeli v izhodišču oceno ≥ 20 po lestvici YMRS.
ABILIFY in one or more subsets of the paediatric population in the treatment of schizophrenia and in the treatment of bipolar affective disorder (see section 4.2 for information on paediatric use).
ABILIFY za eno ali več podskupin pediatrične populacije pri zdravljenju shizofrenije in bipolarne afektivne motnje (za podatke o uporabi pri pediatrični populaciji glejte poglavje 4.2).
In 2 studies in healthy subjects the median times to the peak plasma concentrations were 1 and 3 hours after dosing.
V dveh študijah pri zdravih osebah so bile največje koncentracije v plazmi dosežene v povprečju eno oziroma
The following adverse reactions had a possible dose response relationship; extrapyramidal disorder (incidences were 10 mg, 9.1 %; 30 mg, 28.8 %; placebo, 1.7 %); and akathisia (incidences were 10 mg, 12.1 %; 30 mg, 20.3 %; placebo, 1.7 %).
Naslednji neželeni učinki bi lahko bili povezani z velikostjo odmerka: ekstrapiramidne motnje (pri uporabi 10 mg odmerka je bila pojavnost 9,1 %; pri uporabi 30 mg odmerka 28,8 %; pri uporabi placeba pa 1,7 %) in akatizija (pri uporabi 10 mg odmerka je bila pojavnost 12,1 %; pri uporabi 30 mg odmerka 20,3 %; pri uporabi placeba pa 1,7 %).
The oral solution contains methyl parahydroxybenzoate and propyl parahydroxybenzoate.
Peroralna raztopina vsebuje metilparahidroksibenzoat in propilparahidroksibenzoat.
When considering concomitant administration of ketoconazole or other strong CYP3A4 inhibitors with aripiprazole, potential benefits should outweigh the potential risks to the patient.
Pri odločanju o sočasni uporabi ketokonazola ali drugih močnih zaviralcev CYP3A4 z aripiprazolom morajo biti možne koristi za bolnika večje od možnih tveganj.
Comparisons between aripiprazole and placebo in the proportions of patients experiencing potentially clinically significant changes in routine laboratory and lipid parameters (see section 5.1) revealed no medically important differences.
Laboratorijski parametri Primerjava deležev bolnikov s klinično pomembnimi spremembami vrednosti rutinskih laboratorijskih parametrov in vrednosti lipidov (glejte poglavje 5.1) ni pokazala medicinsko pomembnih razlik med aripiprazolom in placebom.
If you see more than one doctor, be sure to tell them that you are receiving ABILIFY.
Če obiskujete več zdravnikov, jih morate seznaniti s tem, da prejemate zdravilo ABILIFY.
• sensitivity to light,
• kožni izpuščaj, • občutljivost na svetlobo,
ABILIFY is ready to use.
Zdravilo ABILIFY je že pripravljeno za uporabo.
Additionally, aripiprazole and dehydro-aripiprazole did not show potential for altering CYP1A2-mediated metabolism in vitro.
Poleg tega aripiprazol in dehidroaripiprazol in vitro nista pokazala potenciala za spreminjanje presnove s CYP1A2.
In the placebocontrolled trials, the mean weight gain was 0.4 kg for placebo and 1.6 kg for aripiprazole.
V s placebom nadzorovanih preskušanjih se je telesna masa pri uporabi placeba v povprečju povečala za 0,4 kg, pri uporabi aripiprazola pa za 1,6 kg.
The observed mean improvement from baseline on the PANSS Excitement Component score at the primary 2-hour endpoint was 5.8 for placebo, 9.6 for lorazepam, and 8.7 for ABILIFY solution for injection.
Ugotovljeno povprečno izboljšanje od izhodišča po ocenjevalni lestvici PANSS za komponento razburjenja je bilo po dveh urah (primarna končna točka) pri bolnikih, ki so jemali placebo 5,8, pri bolnikih, ki so jemali lorazepam 9,6 in pri bolnikih, ki so jemali zdravilo ABILIFY raztopina za injiciranje 8,7.
Parahydroxybenzoate
Parahidroksibenzoati
• feeling "high", having excessive amounts of energy, needing much less sleep than usual, talking very quickly with racing ideas and sometimes severe irritability.
• evforično razpoloženje, pretirana energija, zmanjšana potreba po spanju, hitro govorjenje s prehitevajočimi mislimi in občasno huda razdražljivost.
2 mg aspartame (E 951) and 0.075 mg lactose per orodispersible tablet
2 mg aspartama (E 951) in 0,075 mg laktoze na orodisperzibilno tableto
PET-bottles with polypropylene child-resistant closure containing 50 mL, 150 mL or 480 mL per bottle.
Plastenke iz PET, ki imajo polipropilensko za otroke varno zaporko in vsebujejo 50 ml, 150 ml ali 480 ml na plastenko.
ABILIFY solution for injection should not be administered intravenously or subcutaneously.
Zdravila ABILIFY raztopina za injiciranje se ne sme dajati intravensko ali subkutano.
The following symptoms may occur in newborn babies, of mothers that have used ABILIFY in the last trimester (last three months of their pregnancy): shaking, muscle stiffness and/or weakness, sleepiness, agitation, breathing problems, and difficulty in feeding.
Pri novorojenčkih mater, ki so v zadnjih treh mesecih nosečnosti uporabljale zdravilo ABILIFY, se lahko pojavijo naslednji simptomi: tresenje, okornost ali šibkost mišic, zaspanost, nemir, težave z dihanjem in motnje hranjenja.
Venous thromboembolism (including pulmonary embolism and deep vein thrombosis) Hypertension
Žilne bolezni ortostatska hipotenzija venska trombembolija (vključno s pljučno embolijo in globoko vensko trombozo) hipertenzija sinkopa
5 How to store ABILIFY Contents of the pack and other information
Shranjevanje zdravila ABILIFY Vsebina pakiranja in dodatne informacije
The aripiprazole AUC in the first 2 hours after an intramuscular injection was 90 % greater than the AUC after the same dose as a tablet; systemic exposure was generally similar between the 2 formulations.
Prvi 2 uri po intramuskularnem injiciranju je vrednost AUC aripiprazola za 90 % večja od vrednosti AUC po prejemu istega odmerka v obliki tablet.
ABILIFY is used to treat adults and adolescents aged 13 years and older who suffer from a condition with symptoms such as feeling "high", having excessive amounts of energy, needing much less sleep than usual, talking very quickly with racing ideas and sometimes severe irritability.
Zdravilo ABILIFY uporabljamo za zdravljenje odraslih in mladostnikov, starih 13 let in več, ki imajo težave s simptomi, kot so evforično razpoloženje, pretirana energija, zmanjšana potreba po spanju, hitro govorjenje s prehitevajočimi mislimi in občasno huda razdražljivost.
ABILIFY is effective in a dose range of 10 mg/day to 30 mg/day.
Zdravilo ABILIFY je učinkovito v razponu odmerkov od 10 mg/dan do 30 mg/dan.
Cases of serotonin syndrome have been reported in patients taking aripiprazole, and possible signs and symptoms for this condition can occur especially in cases of concomitant use with other serotonergic medicinal products, such as selective serotonin reuptake inhibitor/selective serotonin noradrenalin reuptake inhibitor (SSRI/SNRI), or with medicinal products that are known to increase aripiprazole concentrations (see section 4.8).
Znaki in simptomi serotoninskega sindroma se lahko pojavijo še posebej pri sočasni uporabi z drugimi serotoninergičnimi zdravili, kot so selektivni zaviralci privzema serotonina/selektivni zaviralci privzema serotonina in noradrenalina ali z zdravili, ki zvišujejo koncentracijo aripiprazola (glejte poglavje 4.8).
Tics associated with Tourette's disorder: the safety and efficacy of ABILIFY in children and adolescents 6 to 18 years of age have not yet been established.
Trzaji, povezani s Tourettovim sindromom: varnost in učinkovitost zdravila ABILIFY pri otrocih in mladostnikih, starih od 6 do 18 let, še ni bila dokazana.
ABILIFY solution for injection is indicated for the rapid control of agitation and disturbed behaviours in adult patients with schizophrenia or with manic episodes in Bipolar I Disorder, when oral therapy is not appropriate.
ABILIFY raztopina za injiciranje je indicirana za dosego hitre nadzorovanosti agitacije in vedenjskih motenj pri odraslih bolnikih s shizofrenijo in pri maničnih epizodah pri bipolarni motnji I, kadar peroralno zdravljenje ni primerno.
Other strong inhibitors of CYP3A4, such as itraconazole and HIV protease inhibitors may be expected to have similar effects and similar dose reductions should therefore be applied (see section 4.2).
Pričakovati je mogoče, da imajo drugi močni zaviralci CYP3A4, npr. itrakonazol in zaviralci proteaz HIV, podobne učinke, zato je treba odmerjanje podobno zmanjšati (glejte poglavje 4.2).
Receiving ABILIFY with some medicines may mean the doctor will need to change your dose of ABILIFY or the other medicines.
Če prejemate zdravilo ABILIFY z nekaterimi drugimi zdravili, bo morda zdravnik moral spremeniti vaš odmerek zdravila ABILIFY ali drugih zdravil.
Somnolence/sedation and extrapyramidal disorder were reported very commonly (≥ 1/10), and dry mouth, increased appetite, and orthostatic hypotension were reported commonly (≥ 1/100, < 1/10).
Somnolenca/sedacija in ekstrapiramidne motnje so bili zelo pogosti (≥ 1/10), suha usta, povečan apetit in ortostatska hipotenzija pa pogosti (≥ 1/100, < 1/10) neželeni učinki.
A vial provides 9.75 mg in 1.3 mL.
Viala vsebuje 9,75 mg v 1,3 ml.
• certain medicines to treat HIV infection (such as efavirenz, nevirapine, an protease inhibitors e.g. indinavir, ritonavir)
• določena zdravila za zdravljenje okužbe s HIV (kot so efavirenz, nevirapin, zaviralci proteaz,
A combination of ABILIFY with medicines taken for anxiety might make you feel drowsy or dizzy.
Zdravilo ABILIFY skupaj z zdravili za zdravljenje anksioznosti (tesnobe) lahko povzroči zaspanost ali omotičnost.
If you take more ABILIFY than you should
Če ste dobili večji odmerek zdravila ABILIFY, kot bi smeli
Taking ABILIFY with some medicines may mean the doctor will need to change your dose of ABILIFY or the other medicines.
Če jemljete zdravilo ABILIFY z nekaterimi drugimi zdravili, bo morda zdravnik moral spremeniti vaš odmerek zdravila ABILIFY ali drugih zdravil.
Orodispersible tablets
Orodisperzibilne tablete
Class effect: Symptoms of dystonia, prolonged abnormal contractions of muscle groups, may occur in susceptible individuals during the first few days of treatment.
Učinek zdravil iz te skupine (“Class Effect”) - V prvih nekaj dneh zdravljenja se lahko pri dovzetnih posameznikih pojavijo simptomi distonije, podaljšane nenormalne kontrakcije mišičnih skupin.
In CYP2D6 poor metabolisers, concomitant use of strong inhibitors of CYP3A4 may result in higher plasma concentrations of aripiprazole compared to that in CYP2D6 extensive metabolizers.
Pri osebah, ki slabo presnavljajo s CYP2D6 lahko sočasna uporaba z močnimi zaviralci CYP3A4 povzroči večjo koncentracijo aripiprazola v plazmi kot pri osebah, ki dobro presnavljajo s CYP2D6.
In a haloperidol-controlled trial, the proportion of responder patients maintaining response to medicinal product at 52-weeks was similar in both groups (aripiprazole 77 % and haloperidol 73 %).
V preskušanju, nadzorovanems haloperidolom, je bil delež odzivnih bolnikov, pri katerih se je odziv na zdravilo ohranil po 52 tednih, v obeh skupinah podoben (peroralni aripiprazol 77 % in haloperidol 73 %).
In a relative bioavailability study comparing the pharmacokinetics of 30 mg aripiprazole as the oral solution to 30 mg aripiprazole tablets in healthy subjects, the solution to the tablet ratio of geometric mean Cmax values was 122 % (n = 30).
Ko so v študiji relativne biološke uporabnosti pri zdravih prostovoljcih primerjali farmakokinetiko 30 mg aripiprazola v peroralni raztopini s 30 mg aripiprazola v tabletah, je bilo razmerje vrednosti geometrijskih sredin Cmax med raztopino in tabletami 122 % (n = 30).
The safety and efficacy of ABILIFY in the treatment of schizophrenia or manic episodes in Bipolar I Disorder in patients aged 65 years and older has not been established.
Varnost in učinkovitost zdravila ABILIFY nista ugotovljeni pri zdravljenju shizofrenije ali maničnih epizod pri bipolarni motnji I pri bolnikih, starih 65 let in starejših.
• hearing, seeing or sensing things which are not there, suspiciousness, mistaken beliefs,
• slišanje, videnje ali občutenje stvari, ki jih dejansko ni, sumničavost, zmotna prepričanja, nepovezano govorjenje in vedenje ter čustvena praznost.
What ABILIFY looks like and contents of the pack
Izgled zdravila ABILIFY in vsebina pakiranja
Adjunctive aripiprazole demonstrated superiority over placebo on the secondary outcome measure in Clinical Global Impression - Bipolar version (CGI-BP) Severity of Illness (SOI; mania) scores.
Dodatno zdravljenje z aripiprazolom se je izkazalo za boljše od placeba tudi pri sekundarnem merilu izida, oceni resnosti bolezni (SOI, Severity of Illness; manija) po lestvici globalnega kliničnega vtisa glede na stopnjo bipolarne motnje (CGI-BP, Clinical Global Impression
ABILIFY is given when treatment with oral formulations is not appropriate.
Zdravilo ABILIFY uporabljamo, če zdravljenje s peroralnimi farmacevtskimi oblikami ni primerno.
The efficacy of ABILIFY solution for injection in patients with agitation and disturbed behaviours has not been established related to conditions other than schizophrenia and manic episodes in Bipolar I Disorder.
Učinkovitost zdravila ABILIFY raztopina za injiciranje pri bolnikih z agitacijo in vedenjskimi motnjami ni bila dokazana v povezavi z drugimi stanji razen s shizofrenijo in z maničnimi epizodami pri bipolarni motnji I.
Your doctor will change your treatment to oral ABILIFY as soon as appropriate.
Zdravnik bo takoj, ko bo to mogoče, zdravljenje spremenil in vam predpisal peroralno zdravljenje z zdravilom ABILIFY.
Also contains sulfobutylether b-cyclodextrin, tartaric acid, sodium hydroxide, and water for injections.
Vsebuje tudi sulfobutileter betaciklodekstrin, vinsko kislino, natrijev hidroksid in vodo za injekcije.
Treatment should be initiated at 2 mg (using ABILIFY oral solution 1 mg/mL) for 2 days, titrated to 5 mg for 2 additional days to reach the recommended daily dose of 10 mg.
Zdravljenje je treba uvesti v odmerku 2 mg (uporaba zdravila ABILIFY v obliki peroralne raztopine 1 mg/ml), ki ga bolnik jemlje 2 dni, nato pa se odmerek poveča do odmerka 5 mg, ki ga bolnik jemlje še dodatna 2 dni.
In clinical studies, 10 mg/day to 30 mg/day doses of aripiprazole had no significant effect on the metabolism of substrates of CYP2D6 (dextromethorphan/3-methoxymorphinan ratio), CYP2C9 (warfarin), CYP2C19 (omeprazole), and CYP3A4 (dextromethorphan).
V kliničnih študijah odmerki od 10 mg do 30 mg aripiprazola na dan niso pomembno vplivali na presnovo substratov CYP2D6 (razmerje dekstrometorfan/3-metoksimorfinan), CYP2C9 (varfarin), CYP2C19 (omeprazol) ali CYP3A4 (dekstrometorfan).
The safety profile in a 26-week open-label extension trial was similar to that observed in the shortterm, placebo-controlled trial.
podaljšanem preskušanju je bil profil varnosti podoben profilu varnosti v kratkotrajnem, s placebom nadzorovanem preskušanju.
• withdrawal symptoms in newborn babies in case of exposure during pregnancy,
• odtegnitveni simptomi pri novorojenčkih v primeru izpostavljenosti zdravilu v času nosečnosti, • dolgotrajna in/ali boleča erekcija,
Patients who have taken too much aripiprazole have experienced the following symptoms:
Bolniki, ki so vzeli večji odmerek aripiprazola, kot bi smeli, so imeli naslednje simptome:
Management of overdose should concentrate on supportive therapy, maintaining an adequate airway, oxygenation and ventilation, and management of symptoms.
vzdrževanje ustreznega stanja dihal, oksigenacijo in ventilacijo ter obvladovanje simptomov.
Always take the tablet with water and swallow it whole.
Ni pomembno, ali tableto vzamete s hrano ali brez nje, vedno pa jo vzemite z vodo in jo pogoltnite celo.
Neuroleptic Malignant Syndrome Grand mal convulsion Serotonin syndrome Speech disorder
Bolezni živčevja akatizija ekstrapiramidne motnje tremor glavobol sedacija somnolenca omotica tardivna diskinezija distonija nevroleptični maligni sindrom generalizirana konvulzija serotoninski sindrom motnje govora
These are called impulse control disorders and can include behaviours such as addictive gambling, excessive eating or spending, an abnormally high sex drive or preoccupation with an increase in sexual thoughts or feelings.
kot so odvisnost od hazardiranja, čezmerno uživanje hrane ali trošenje denarja, nenormalno povečan libido ali preokupacija z mislimi na spolnost ali spolnimi občutki.
In clinical studies, oral doses of 10 mg/day to 30 mg/day of aripiprazole had no significant effect on the metabolism of substrates of CYP2D6 (dextromethorphan/3-methoxymorphinan ratio), CYP2C9 (warfarin), CYP2C19 (omeprazole), and CYP3A4 (dextromethorphan).
V kliničnih študijah peroralni odmerki od 10 mg do 30 mg aripiprazola na dan niso pomembno vplivali na presnovo substratov CYP2D6 (razmerje dekstrometorfan/3-metoksimorfinan), CYP2C9 (varfarin), CYP2C19 (omeprazol) ali CYP3A4 (dekstrometorfan).
All ADRs are listed by system organ class and frequency; very common (≥ 1/10), common (≥ 1/100 to
Vsi neželeni učinki zdravila so našteti po organskih sistemih in pogostnosti: zelo pogosti (≥ 1/10),
Schizophrenia: in a long-term 52-week controlled trial, aripiprazole-treated patients had an overalllower incidence (25.8 %) of EPS including Parkinsonism, akathisia, dystonia and dyskinesia compared with those treated with haloperidol (57.3 %).
Shizofrenija: v dolgoročnem 52-tedenskem nadzorovanem preskušanju je bila celotna incidenca EPS (vključno s parkinsonizmom, akatizijo, distonijo in diskinezijo) manjša (25,8 %) pri bolnikih, ki so dobivali aripiprazol, kot pri tistih, ki so dobivali haloperidol (57,3 %).
Aripiprazole should be used cautiously in patients at risk for aspiration pneumonia.
Pri bolnikih s tveganjem za aspiracijsko pljučnicoje treba aripiprazol uporabljati previdno.
A vial contains 9.75 mg (1.3 mL) aripiprazole.
Viala vsebuje 9,75 mg (1,3 ml) aripiprazola.
Aripiprazole group showed an improvement of 14.97 on TTS-YGTSS change from baseline to week 10 as compared with an improvement of 9.62 in the placebo group.
Pri skupini, ki je prejemala aripiprazol, je bilo 10. teden vidno izboljšanje za 14,97 točk po lestvici TTS-YGTSS od izhodiščne vrednosti, v primerjavi z izboljšanjem za 9,62 točke pri skupini, ki je prejemala placebo.
Manic episodes in Bipolar I Disorder: in a 12-week controlled trial, the incidence of EPS was 23.5 % for aripiprazole-treated patients and 53.3 % for haloperidol-treated patients.
Manične epizode pri bipolarni motnji I: v 12-tedenskem nadzorovanem preskušanju je bila pojavnost EPS pri bolnikih, ki so se zdravili z aripiprazolom 23,5 %, pri bolnikih, ki so se zdravili s haloperidolom pa 53,3 %.
No specific interaction studies have been performed with ABILIFY solution for injection.
Študij medsebojnega delovanja z zdravilom ABILIFY raztopina za injiciranje niso izvedli.
Upon discontinuation of the CYP2D6 or CYP3A4 inhibitor, the dosage of aripiprazole should be increased to the level prior to the initiation of the concomitant therapy.
Po prenehanju zdravljenja z zaviralcem CYP2D6 ali CYP3A4 je treba odmerjanje aripiprazola zvečati na raven, kakršna je bila pred uvedbo sočasne terapije.
14 × 1 orodispersible tablets 28 × 1 orodispersible tablets 49 × 1 orodispersible tablets
14 × 1 orodisperzibilna tableta 28 × 1 orodisperzibilna tableta 49 × 1 orodisperzibilna tableta
An additional finding was cholelithiasis as a consequence of precipitation of sulphate conjugates of hydroxy metabolites of aripiprazole in the bile of monkeys after repeated oral dosing at 25 mg/kg/day to 125 mg/kg/day (1 to 3 times the mean steady-state AUC at the maximum recommended clinical dose or 16 to 81 times the maximum recommended human dose based on mg/m2).
Dodaten izsledek je bila holelitiaza zaradi precipitacije sulfatnih konjugatov hidroksipresnovkov aripiprazola v žolču opic po ponavljajočem odmerjanju od 25 mg/kg/dan do 125 mg/kg/dan (1- do 3kratna srednja AUC v stanju dinamičnega ravnovesja ob največjem priporočenem kliničnem odmerku ali 16- do 81-kratni največji priporočeni odmerek za človeka glede na mg/m2).
Immediately upon opening the blister, using dry hands, remove the tablet and place the entire orodispersible tablet on the tongue.
Takoj ko odprete omot, orodisperzibilno tableto s suhimi rokami primite in celo položite na jezik.
Each carton contains one single-use type I glass vial with a rubber butyl stopper and a "tear-off" aluminium seal.
Ena škatla vsebuje 1 vialo za enkratno uporabo iz stekla tipa I, zaprto z zamaškom iz butilne gume in aluminijasto odtržno zaporko.
Based on in vitro studies, CYP3A4 and CYP2D6 enzymes are responsible for dehydrogenation and hydroxylation of aripiprazole, and N-dealkylation is catalysed by CYP3A4.
Na podlagi raziskav in vitro so za dehidrogenacijo in hidroksilacijo aripiprazola odgovorni encimi CYP3A4 in CYP2D6, N-dealkilacijo pa katalizira
ABILIFY is not recommended for use in patients with schizophrenia below 15 years of age due to insufficient data on safety and efficacy (see sections 4.8 and 5.1).
Zaradi nezadostnih podatkov o varnosti in učinkovitosti uporaba zdravila ABILIFY pri bolnikih s shizofrenijo, mlajših od 15 let, ni priporočljiva (glejte poglavji 4.8 in 5.1).
Dosing in these trials was initiated at 2 mg/day, increased to 5 mg/day after one week, and increased by 5 mg/day in weekly increments to the target dose.
Odmerek so po enem tednu povečali do 5 mg/dan, nato pa so ga do ciljnega odmerka povečevali za
• The other ingredients are calcium silicate, croscarmellose sodium, crospovidone, silicon dioxide, xylitol, microcrystalline cellulose, aspartame, acesulfame potassium, vanilla flavour (contains lactose), tartaric acid and magnesium stearate.
• Druge sestavine zdravila so kalcijev silikat, premreženi natrijev karmelozat, krospovidon, silicijev dioksid, ksilitol, mikrokristalna celuloza, aspartam, kalcijev acesulfamat, aroma vanilije (vsebuje laktozo), vinska kislina, magnezijev stearat.
Patients with attention deficit hyperactivity disorder (ADHD) comorbidity Despite the high comorbidity frequency of Bipolar I Disorder and ADHD, very limited safety data are available on concomitant use of aripiprazole and stimulants; therefore, extreme caution should be taken when these medicinal products are co-administered.
Bolniki s sočasno motnjo pomanjkanja pozornosti (ADHD - Attention deficit hyperactivity disorder) Kljub pogosti sočasni obolevnosti za bipolarno motnjo I in motnjo pomanjkanja pozornosti je na voljo zelo malo podatkov o sočasni uporabi aripiprazola in stimulansov.
• antidepressants or herbal remedy used to treat depression and anxiety (such as fluoxetine,
• antidepresive ali pripravke rastlinskega izvora proti depresiji in tesnobnosti (kot so fluoksetin,
• Inability to resist the impulse, drive or temptation to perform an action that could be harmful to you or others, which may include: strong impulse to gamble excessively despite serious personal or family consequences altered or increased sexual interest and behaviour of significant concern to you or to others, for example, an increased sexual drive uncontrollable excessive shopping binge eating (eating large amounts of food in a short time period) or compulsive eating (eating more food than normal and more than is needed to satisfy your hunger) a tendency to wander away.
- močna želja po čezmernem hazardiranju ne glede na posledice za vas ali za družino, - spremenjeno ali povečano spolno zanimanje in vedenje, ki vam ali drugim povzroča znatno zaskrbljenost, na primer povečan libido, - čezmerno nakupovanje ali trošenje denarja, ki ju ne morete nadzorovati, - prenajedanje (uživanje velikih količin hrane v kratkem obdobju) ali kompulzivno uživanje hrane (uživanje večjih količin hrane od normalnih in več, kot je potrebno za potešitev lakote), - nagnjenost k tavanju.